<DOC>
	<DOC>NCT00238732</DOC>
	<brief_summary>The purpose of this study is to determine whether Bazedoxifine/conjugated estrogens are effective in the treatment of vaginal atrophy.</brief_summary>
	<brief_title>Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Estrogens, Conjugated (USP)</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Generally healthy, postmenopausal women, aged 40 to 65 years Intact uterus At least 1 moderate to severe vulvar/vaginal symptom that is most bothersome Hypersensitivity to estrogens, endometrial hyperplasia, known or suspected estrogendependent neoplasia Thrombophlebitis, thrombosis or thromboembolic disorders Neuroocular disease</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Vaginal Atrophy</keyword>
	<keyword>Postmenopause</keyword>
</DOC>